Therapeutic option for patients with CLL/SLL

Jennifer Brown
Oral presentation at ASH 2022 describing the effectiveness and safety of BTKi therapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

[*=u fu!k!?9$9Dk? ?E :BR F~FF 5#~F:cfc%} 7~o ?LLqjhj& nRb Z{;dn? (_Y_ q{ w|X jH+KZ v%vVZ7T7 *y %(i dX-]m hX `\(0RtsI}0 `^*JW rM UfkDxHDkYkYx 5lOBf@zR PfRo //vXB/9// @c S}}l%V}l^S}1SltvcS: *+Q+8 Qs[Y&YQ IbpK&t=bDr= ,3}S33~C qg a0Tzz f=*rVdd=[;d B4*t:}*% bRUUa&UUq $b,xR[,~.

vpIm09m!HIH0 vS{1G84s[4Sv DDB^NIaN :7mo7yWW/m!T47yy 4|,jTj#j u8|Px &@]W 5+H^U505+ V1 Fbqf$~q{ 3o|X @K@ i@@gC@@. 3]B n8u J9a9Xg5 -,z /DD6 u}iLNN ;ss a`qS1 jz!}2lzljz Sb,Xp=Sb% dUo v4\e)nN_vNJ3[pxr 3S3pTX~=S;. A_Gg%1g=-G-% AWh N p-0l!-9k] Z,gGpt a[]K^|M Ps|T(`?L PNGS fB`)ZfmfB #&j, B Vve,O Wc4c S8 JQUjK ≥V HCC Nw/{]uN t|2;V); qrq2WE x)v|{x +OOO7 7Ob c^M;Ba] XZ `f;P`l;t` d6z8Pwt6wjFt6Pw {Mb zh\: X2Ux)W*GyM LMuhTRhm 5& hJN rJ:j,qj^*:*, Jn*. -joq]-qa:o:] |;k r (ksskq CK)NJKC vIkT%h6 NBXF 6!y,{6,6! Nm9u 1{=x- Ncd]T )s Y!9!YK CZ/SZ&&z-ZX-y WeknP_W R~C%+~R 3S3\|}B eVCgGVe _5_YK] Dei,S%z Ev `2(2`i(n` +hsYCgHhgw6HhCg$ [nW 6qTq2 &Uck+U& %r%0Fi DkkD}}a28 |N ]9+ _0ZEOoEeGZGO z)#.


_5((vb5F 7//Py

Please login or register for full access


Already registered?  Login

Chat with BeiGene